{
    "clinical_study": {
        "@rank": "93911", 
        "arm_group": [
            {
                "arm_group_label": "ABT-126 Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "ABT-126 Low Dose"
            }, 
            {
                "arm_group_label": "ABT-126 High Dose", 
                "arm_group_type": "Experimental", 
                "description": "ABT-126 High Dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an efficacy study evaluating a experimental treatment for cognitive deficits in\n      adults with schizophrenia."
        }, 
        "brief_title": "A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "Safety and Efficacy Study for Cognitive Deficits in Adult Subjects with Schizophrenia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a current Diagnostic and Statistical Manual of Mental Disorders-, 4th Edition,\n             Text Revision (DSM-IV-TR) diagnosis of schizophrenia confirmed by the\n             Mini-International Neuropsychiatric Interview (M.I.N.I.).\n\n          -  Is clinically stable while receiving a regimen of one or two allowable antipsychotic\n             medications; lack of hospitalizations in 4 months prior to initial screening visit;\n             taking the same antipsychotic medication(s) for at least 8 weeks prior to baseline\n             visit; core positive symptoms of Positive and Negative Syndrome Scale (PANSS) no\n             worse than moderate in severity throughout screening period of at least 4 weeks.\n\n          -  Has been diagnosed with or treated for schizophrenia for at least 2 years prior to\n             initial screening visit.\n\n          -  Has had continuity in psychiatric care (e.g., mental health system, clinic or\n             physician) for at least 6 months prior to initial screening visit.\n\n          -  Has an identified contact person (e.g., family member, social worker, case worker, or\n             nurse) that can provide support to the subject to ensure compliance with protocol\n             requirements.\n\n        Exclusion Criteria:\n\n          -  In the Investigator's judgment, has a current or past diagnosis of schizoaffective\n             disorder, bipolar disorder, manic episode, dementia, post traumatic stress disorder,\n             or obsessive-compulsive disorder, or the subject has a current major depressive\n             episode.\n\n          -  Has a positive urine drug screen for cocaine, phencyclidine (PCP), opiates (unless\n             duly prescribed), benzodiazepines (unless duly prescribed), marijuana, or\n             amphetamines during the Screening Period.\n\n          -  Has a current or past history of seizures, with the exception of a single febrile\n             seizure occurring prior to 6 years of age.\n\n          -  Has a clinically significant abnormal electrocardiogram (ECG) at Screening Visit 1 as\n             determined by the Investigator.\n\n          -  Has any risk factors for Torsades de Pointes (TdP)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678755", 
            "org_study_id": "M13-608"
        }, 
        "intervention": [
            {
                "arm_group_label": "ABT-126 Low Dose", 
                "description": "ABT-126 Low Dose", 
                "intervention_name": "ABT-126", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ABT-126 High Dose", 
                "description": "ABT-126 High Dose", 
                "intervention_name": "ABT-126", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "schizophrenia", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chino", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91710"
                    }, 
                    "name": "Site Reference ID/Investigator# 74436"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92845"
                    }, 
                    "name": "Site Reference ID/Investigator# 72704"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "National City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91950"
                    }, 
                    "name": "Site Reference ID/Investigator# 72699"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }, 
                    "name": "Site Reference ID/Investigator# 73983"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Site Reference ID/Investigator# 73236"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }, 
                    "name": "Site Reference ID/Investigator# 86974"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }, 
                    "name": "Site Reference ID/Investigator# 72701"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Site Reference ID/Investigator# 75314"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Site Reference ID/Investigator# 75146"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Site Reference ID/Investigator# 75654"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60640"
                    }, 
                    "name": "Site Reference ID/Investigator# 72703"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoffman Estates", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60169"
                    }, 
                    "name": "Site Reference ID/Investigator# 76534"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Charles", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70629"
                    }, 
                    "name": "Site Reference ID/Investigator# 73984"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63109"
                    }, 
                    "name": "Site Reference ID/Investigator# 73981"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08053"
                    }, 
                    "name": "Site Reference ID/Investigator# 89553"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cedarhurst", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11516"
                    }, 
                    "name": "Site Reference ID/Investigator# 72700"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Site Reference ID/Investigator# 73982"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73116"
                    }, 
                    "name": "Site Reference ID/Investigator# 113035"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DeSoto", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75115"
                    }, 
                    "name": "Site Reference ID/Investigator# 72702"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77008"
                    }, 
                    "name": "Site Reference ID/Investigator# 75147"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "George  Haig, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Rater based interview", 
            "measure": "Cognition:  MCCB (MATRICS Consensus Cognitive Battery) change from baseline to week 12", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678755"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Rater based interview", 
                "measure": "Functioning:  UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)", 
                "safety_issue": "No", 
                "time_frame": "Measurements from screening period up through week 12"
            }, 
            {
                "description": "Rater based interview", 
                "measure": "Symptom Severity:  PANSS (Positive and Negative Syndrome Scale)", 
                "safety_issue": "No", 
                "time_frame": "Measurements from screening period up through week 12"
            }, 
            {
                "description": "Rater based interview", 
                "measure": "Symptom Severity:  NSA-16 (16-item version of the Negative Symptom Assessment Scale)", 
                "safety_issue": "No", 
                "time_frame": "Measurements from screening period up through week 12"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}